2.21k followers • 16 symbols Watchlist by Motif Investing
Global adoption of minimally invasive procedures could spark new growth. The global minimally invasive surgery market is forecast to reach $35.5 billion by the end of 2016 with compound annual growth rate ("CAGR") of 8.2%.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings projections for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted EPS of $1.53–$1.58 for
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%, YoY organic
How Boston Scientific and Abbott Laboratories Stack UpStock price movementsOn February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! There are a number of reasons that attract investors towardsRead More...
Where Druckenmiller Suggests Investing amid Market Fluctuation(Continued from Prior Part)Druckenmiller’s top buysIn this article, we’ll discuss Stanley Druckenmiller’s top buys in the fourth quarter. Druckenmiller seemed to be positive on
Richard Blum, the head of private-equity firm Blum Capital, also bought Synopsys stock and sold Hologic stock in January.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...
The world's largest big-box retailer outperformed expectations on both its top and bottom lines for fiscal Q4: $1.41 per share surpassed the $1.33 in the Zacks consensus.
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
Medtronic (MDT) gains on strength in the Minimally Invasive Therapies and Restorative Therapies Groups along with solid performance across emerging markets in Q3.
Investing.com -- The U.S. stock market reopened after the long weekend with a whimper, as sobering comments from the Cleveland Federal Reserve President Loretta Mester grabbed attention while traders waited for news of progress on trade talks with China.
Investing.com - Medtronic (NYSE:MDT) reported third quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.